Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117441 | 0.84 | ALOX15 (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL656941 | 0.83 | ALOX15 (0.59) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL12611856 | 0.81 | ALDH1A1 (0.63) | MAOBAOC3ALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL12824120 | 0.81 | ALDH1A1 (0.54) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2171542 | 0.81 | MAOB (0.57) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL9279028 | 0.79 | ALDH1A1 (0.51) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL13279565 | 0.79 | MEN1 (0.63) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1619089 | 0.79 | NPC1 (0.53) | MAOBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1462002 | 0.78 | NLRP3 (0.50) | ALDH1A1EPHX2HRH3MEN1KMT2A | |
| SCHEMBL24112748 | 0.77 | ALDH1A1 (0.60) | MAOBAOC3ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2626072-A1 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2623491-A2 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-1984369-A2 | NITROIMIDAZOLE COMPOUNDS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008107677-A2 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SENEXIS LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007028022-A2 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1730128-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060111357-A1 | Quinoline compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1572212-A2 | QUINOLINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM Pharma A/S (DK) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052370-A2 | QUINOLINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052371-A2 | CYCLIC QUINOLINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111357-A1 | Quinoline compounds for use in mch receptor related disorders | MCHR2, MCHR1, MC1R | MAOB 549/4885AOC3 2687/4885ALDH1A1 3604/4885 |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | MAOB 1145/4885AOC3 2299/4885ALDH1A1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.